Prespecified 2-year follow-up of the SIRONA trial (482 patients, femoropopliteal disease): sirolimus- vs paclitaxel-coated balloons had similar quality of life, patency (64.6% vs 67.2%) and freedom from TLR (91.2% vs 88.1%); mortality 6.3% vs 3.7% (P=0.21).
RCTn = 482
Teichgräber et al. 2-Year Patient-Centered and Clinical Outcomes of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Artery Disease